InvestorWire NewsRoom

Article

Podcast Interview Highlights POC Health Data Testing Using Innovative Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Platform
October 8, 2021

Podcast Interview Highlights POC Health Data Testing Using Innovative Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Platform

  • Pharmacy services developer Avricore Health recently completed the initial phase of rolling out its HealthTab(TM) platform
  • HealthTab(TM) partners with other health technology platforms to collect data from blood or other molecular samples to test them for illnesses ranging from COVID and flu to heart disease and diabetes
  • Avricore’s platform is designed to not only provide medical condition information to patients, but to share it seamlessly with medical providers and researchers
  • The company’s initial rollout took place through pharmacies in Ontario, Canada, but Avricore intends to continue expanding throughout Canada, into the United States and eventually into Europe

Health diagnostics technology innovator Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) has completed the initial rollout of its point of care platform for providing patients with lab-quality results regarding COVID and other illnesses, and the company was featured just recently in a Bell2Bell podcast discussing its history, its next goals and the plans it has for development farther down the road. 

“I’ve always really believed that we need a true health care system that values early detection and screening if we really want to make sure that we’re not only saving lives but saving health care dollars in the future,” Avricore CEO Hector Bremner told Bell2Bell’s Stuart Smith (https://ibn.fm/PxlqO). “We’re really passionate about leading this charge. … We’ve now got a company that is in great shape and fully funded. And we’re growing, and we’ve got really a lot of blue sky ahead of us.”

Avricore’s flagship HealthTab(TM) platform partners currently with Abbott Rapid Diagnostics’ Afinion 2(TM) and ID Now(TM) analyzers, as well as Abaxis Global Diagnostics’ Piccolo Xpress to conduct blood or molecular testing at a neighborhood pharmacy and then shares the data from the tests not only with the patient, but also with medical professionals and researchers without compromising health privacy. 

“Really, the objective here is to create a global network of pharmacies reporting back real-time information on patient data and that can be used for study and research purposes, which is a very, very high demand out there in the sector,” Bremner said. 

For the patient’s part, once the simple sample is collected testing takes about 15 minutes to deliver the results. The initial rollout has been accomplished by partnering with the Shoppers Drug Mart pharmacy network in Ontario, Canada, but the company anticipates continuing to expand through Shoppers Drug Mart’s almost 1,800 pharmacies across Canada, adding other pharmacies, and then entering the United States and the United Kingdom as well. 

“The nice thing is all this technology that we use, everything that we’re doing down there (in the United States), is already approved so we are not at a sort of regulatory or approval risk at any level expanding internationally,” he said. “We’re also really excited about opportunities in the UK and EU, which, I think people just don’t understand how big a market that really is — it’s still bigger than China and it is a place where I think we can do business reliably. Between the U.S., UK and Canada, there’s about 110,000 pharmacies.”

Bremner said Avricore Health is also generating interest among Latin American and Caribbean countries for applications of its network in travel-related infectious disease diagnostics. 

The company’s cloud-based technology provides a network for high-quality analysis not only for illnesses such as COVID and influenza, but heart disease and diabetes as well, facilitating data-based follow-ups with medical providers. 

The global point-of-care diagnostics market was measured at nearly $34.5 billion in revenue last year by Fortune Business Insights, and it is expected to continue growing at a compound annual growth rate (“CAGR”) of 9.4 percent through 2028 (https://ibn.fm/WFy4E). 

For more information, visit the company’s website at www.AvricoreHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).